Nonetheless, the FDA issued a warning for most GLP-1R–targeted therapies for patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome, which remains in place today (41). Here, GLP1R is linked to medullary thyroid gland carcinoma.